Oakrum Pharma Announces the Launch of Pyrimethamine 25mg Tablets in the United States

ST. LOUIS, March 11, 2020 /PRNewswire/ -- Oakrum Pharma, LLC ("Oakrum") announced today the launch and commercial distribution of pyrimethamine 25mg tablets in the United States.

With the launch of pyrimethamine 25mg tablets today, Oakrum expects to be the first to bring generic pyrimethamine 25mg tablets, as an authorized generic, to the market.  Oakrum intends to distribute this product through Optime Care Inc., a St. Louis-based, nationally licensed, specialty pharmacy and wholesale distributor.  Oakrum selected Optime Care as its partner for this product because of Optime Care's commitment to provide patients and their caregivers with dedicated programs and services in support of this important drug. 

About Oakrum Pharma, LLC 

Oakrum Pharma, LLC is a privately-owned biopharmaceutical company focusing on development and commercialization of affordable drug therapies.  For more information, visit www.oakrumpharma.com.  

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Oakrum are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Oakrum intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Oakrum's actual results to be materially different from its historical results or from any results expressed or implied by said statements. Oakrum's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions and the need for regulatory approvals, Oakrum's ability to fund development of its technology and to successfully complete clinical trials, the length of time and costs required to complete clinical trials and to submit applications for regulatory approvals, products developed by competing companies, commercial acceptance of Oakrum's products, and other factors. Oakrum is not responsible for updating events occurring after the date of this press release.

SOURCE Oakrum Pharma, LLC

Related Links

https://www.oakrumpharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED